Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma

Christopher Schutt, Klaus Bumm, Leonardo Mirandola, Giovanni Bernardini, Nicholas D. Cunha, Lukman Tijani, Diane Nguyen, Joehassin Cordero, Marjorie R. Jenkins, Everardo Cobos, W. Martin Kast, Maurizio Chiriva-Internati

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.

Original languageEnglish (US)
Pages (from-to)22-42
Number of pages21
JournalInternational Reviews of Immunology
Volume31
Issue number1
DOIs
StatePublished - Feb 1 2012

Keywords

  • CRT
  • Cancer vaccines
  • EGFR
  • HNSCC
  • HPV

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Schutt, C., Bumm, K., Mirandola, L., Bernardini, G., Cunha, N. D., Tijani, L., Nguyen, D., Cordero, J., Jenkins, M. R., Cobos, E., Kast, W. M., & Chiriva-Internati, M. (2012). Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. International Reviews of Immunology, 31(1), 22-42. https://doi.org/10.3109/08830185.2011.637253